CA2650401A1 - Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators - Google Patents

Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators Download PDF

Info

Publication number
CA2650401A1
CA2650401A1 CA002650401A CA2650401A CA2650401A1 CA 2650401 A1 CA2650401 A1 CA 2650401A1 CA 002650401 A CA002650401 A CA 002650401A CA 2650401 A CA2650401 A CA 2650401A CA 2650401 A1 CA2650401 A1 CA 2650401A1
Authority
CA
Canada
Prior art keywords
6alkyl
substituted
unsubstituted
halogen
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002650401A
Other languages
English (en)
French (fr)
Inventor
Joseph L. Duffy
Scott Edmondson
Alexa Hansen
Cheng Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2650401A1 publication Critical patent/CA2650401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
CA002650401A 2006-04-14 2007-04-10 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators Abandoned CA2650401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79213406P 2006-04-14 2006-04-14
US60/792,134 2006-04-14
PCT/US2007/008956 WO2007120718A2 (en) 2006-04-14 2007-04-10 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators

Publications (1)

Publication Number Publication Date
CA2650401A1 true CA2650401A1 (en) 2007-10-25

Family

ID=38610151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002650401A Abandoned CA2650401A1 (en) 2006-04-14 2007-04-10 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators

Country Status (8)

Country Link
US (1) US7759352B2 (de)
EP (1) EP2010179B1 (de)
JP (1) JP2009533449A (de)
AT (1) ATE473004T1 (de)
AU (1) AU2007238744A1 (de)
CA (1) CA2650401A1 (de)
DE (1) DE602007007594D1 (de)
WO (1) WO2007120718A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007008868D1 (de) 2006-04-14 2010-10-14 Merck Sharp & Dohme Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
MX2008013237A (es) 2006-04-14 2009-03-06 Merck & Co Inc Imidazol 4-caroxamidas sustituidas como moduladores del receptor colecistoquinina-1.
WO2009001915A1 (ja) * 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
HUE057970T2 (hu) 2018-03-08 2022-06-28 Incyte Corp Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
WO2002055495A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7109216B2 (en) 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20060189591A1 (en) 2003-04-21 2006-08-24 Daiichi Pharmaceutical Co., Ltd. Five-membered heterocyclic derivative
US20050026983A1 (en) 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
AU2004283903B2 (en) 2003-10-20 2010-12-02 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives as cannabinoid receptor modulators
US20050124660A1 (en) 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
WO2005063716A1 (en) 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
EP1735287A1 (de) * 2004-04-03 2006-12-27 Astrazeneca AB Therapeutische mittel
DE602007008868D1 (de) 2006-04-14 2010-10-14 Merck Sharp & Dohme Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
MX2008013237A (es) 2006-04-14 2009-03-06 Merck & Co Inc Imidazol 4-caroxamidas sustituidas como moduladores del receptor colecistoquinina-1.

Also Published As

Publication number Publication date
JP2009533449A (ja) 2009-09-17
US20090281117A1 (en) 2009-11-12
DE602007007594D1 (de) 2010-08-19
AU2007238744A1 (en) 2007-10-25
US7759352B2 (en) 2010-07-20
WO2007120718A2 (en) 2007-10-25
ATE473004T1 (de) 2010-07-15
WO2007120718A3 (en) 2008-07-24
EP2010179A4 (de) 2009-05-06
EP2010179B1 (de) 2010-07-07
EP2010179A2 (de) 2009-01-07

Similar Documents

Publication Publication Date Title
US7977339B2 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
EP2010179B1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
US7858629B2 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
AU2007332867A1 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
EP2114408B1 (de) Substituierte aminopyrimidine als cholecystokinin-1-rezeptormodulatoren
US8318767B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued